Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Prostate cancer frequently metastasizes to bones; however, the detection of metastases can be challenging in rare locations. We present the case of a 76-year-old man with metastatic castration-resistant prostate cancer with lymph nodal and skeletal metastases who underwent 177Lu-prostate-specific membrane antigen (PSMA) therapy. Initial 18F-PSMA PET/CT scan acquired until the midthigh failed to identify metastases in the foot, but posttherapy 177Lu-PSMA scan revealed the presence of metastases in the navicular and cuboid bones of the right foot, which is a very rare finding. This case highlights the limitations of standard PSMA PET/CT acquisition protocol and incremental value of whole-body posttherapy scan.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000005592 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Usefulness of Preradioactive Iodine Scans in Thyroid Cancer.
J Endocr Soc
September 2025
Center for Diabetes and Endocrine Health, Allegheny Health Network, Medicine Institute, Pittsburgh, PA 15017, USA.
Context: There is an evolving role for radioactive iodine (RAI) in thyroid cancer treatment. Radioactive iodine treatment usually involves a pre-RAI whole-body iodine scan and a posttherapy scan. The clinical utility of pre-RAI therapy scans has been increasingly questioned.
View Article and Find Full Text PDFSalivary scintigraphy as a pre-treatment diagnostic tool to predict gland dysfunction following I therapy.
Hell J Nucl Med
August 2025
Department of Nuclear Medicine, The Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu Province, China.
Objective: To evaluate whether pre-treatment salivary gland scintigraphy (SGS) with technetium-99m pertechnetate (TcO) can predict the risk of moderate to severe salivary gland dysfunction and xerostomia in differentiated thyroid cancer (DTC) patients following their first radioiodine-131 (I) therapy.
Subjects And Methods: We retrospectively enrolled 149 DTC patients (107 females, 42 males; mean age 46.6±12.
Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials.
J Nucl Med
August 2025
Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;
Data are emerging on the prognostic significance of quantitative changes on posttherapy SPECT/CT in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving [Lu]Lu-PSMA-617. Our objective was to assess quantitative and visual changes on posttherapy SPECT/CT as prognostic biomarkers for overall survival (OS) among patients in 3 clinical trials: LuPSMA Phase 2 (ANZCTR12615000912583), LuPARP (NCT03874884), and PRINCE (NCT03658447)]. We segmented the total tumor burden on posttherapy [Lu]Lu-PSMA-617 SPECT/CT using an SUV threshold of 3 to measure SUV, SUV, metabolic tumor volume (MTV), and total lesion activity (TLA).
View Article and Find Full Text PDFI-131 Uptake in a Benign Diaphragmatic Mesothelial Cyst Mimicking Thyroid Cancer Metastasis on Post-therapy SPECT/CT.
Clin Nucl Med
October 2025
Department of Radiology.
Radioiodine ablation therapy is commonly used for patients with well-differentiated thyroid cancer. False-positive radioiodine uptake in benign cystic lesions on post-therapy SPECT/CT presents a recognized diagnostic challenge. Here, we present the case of a 33-year-old woman who underwent total thyroidectomy, followed by I-131 radioiodine therapy.
View Article and Find Full Text PDFDesign and Evaluation of a Portable Pinhole SPECT System for Lu Imaging: Monte Carlo Simulations and Experimental Study.
Diagnostics (Basel)
May 2025
BIOEMTECH, 15344 Athens, Greece.
/ Lutetium-177 is a widely used radioisotope in targeted radionuclide therapy, particularly for treating certain types of cancers relying on beta and low-energy gamma emissions, making it suitable for both therapeutic and post-therapy monitoring purposes. The purpose of this study was to evaluate the technical parameters for developing a prototype portable gamma camera dedicated to Lu imaging applications. : The well-validated GATE Monte Carlo toolkit was used to study the characteristics of the system and evaluate its performance in terms of spatial resolution, sensitivity, and image quality.
View Article and Find Full Text PDF